Key facts
- Oncobit’s last known valuation is $26.1M (Oct 2025).
- It has raised $14.9M; the latest was Later Stage VC ($2.4M) in Oct 2025.
- Notable investors include Venture Kick, Kickfund, Avanteca Partners, GF Group Holding, ID Solutions (France) — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Oncobit
- ·The full record, as it builds
Funding rounds
No funding rounds for Oncobit are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oncobit
Developer of critical precision diagnostic and monitoring technology designed to improve patient outcomes. The company's platform provides monitoring of the patient's cancer and optimized therapy management through its cloud-based data analysis and interpretation software, providing clinicians with advanced molecular insights for therapy optimization.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2018
- Employees
- 10
- Website
- oncobit.com/
- Ownership
- Privately Held (backing)
Oncobit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oncobit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oncobit in its N-PORT filings yet. We sweep new filings monthly.